tert-butyl 4-(2-cyanophenyloxy)-1-piperidinecarboxylate | 647014-70-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-(2-cyanophenyloxy)-1-piperidinecarboxylate
• 英文别名: 4-(2-cyano-phenoxy)-piperidine-1-carboxylic acid tert-butyl ester；tert-butyl 4-(2-cyanophenoxy)piperidine-1-carboxylate
• CAS: 647014-70-8
• 化学式: C₁₇H₂₂N₂O₃
• 分子量: 302.373
• InChiKey: VCUKVBNMEXXRJE-UHFFFAOYSA-N

物化性质

• 沸点：
  442.8±35.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  62.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(2-cyanophenyloxy)-1-piperidinecarboxylate 在 盐酸 、 三乙胺 作用下， 以 1,4-二氧六环 、 乙腈 为溶剂， 反应 2.33h， 生成 6-[4-(2-cyanophenoxy)piperidin-1-yl]-N-methylpyridazine-3-carboxamide
  参考文献：
  名称：

  Discovery of Potent, Selective, Orally Bioavailable Stearoyl-CoA Desaturase 1 Inhibitors

  摘要：

  Stearoyl-CoA desaturase 1 (SCD1) catalyzes the committed step in the biosynthesis of monounsaturated fatty acids from saturated, long-chain fatty acids. Studies with SCD1 knockout mice have established that these animals are lean and protected from leptin deficiency-induced and diet-induced obesity, with greater whole body insulin sensitivity than wild-type animals. In this work, we have discovered a series of potent, selective, orally bioavailable SCD1 inhibitors based on a known pyridazine carboxamide template. The representative lead inhibitor 28c also demonstrates excellent cellular activity in blocking the conversion of saturated long-chain fatty acid-CoAs (LCFA-CoAs) to monounsaturated LCFA-CoAs in HepG2 cells.

  DOI：

  10.1021/jm070219p
• 作为产物：
  描述：

  2-氟苯腈 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 以99%的产率得到tert-butyl 4-(2-cyanophenyloxy)-1-piperidinecarboxylate
  参考文献：
  名称：

  WO2007/106705

  摘要：

  公开号：

文献信息

• [EN] SULPHONYLPIPERIDINE DERIVATIVES CONTAINING AN ARYL OR HETEROARYL GROUP FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] DERIVES DE SULPHONYL-PIPERIDINE CONTENANT UN GROUPE ARYLE OU HETEROARYLE, UTILISES COMME INHIBITEURS DE LA METALLOPROTEASE MATRICIELLE
  申请人：ASTRAZENECA AB

  公开号：WO2004006926A1

  公开（公告）日：2004-01-22

  A compound of formula (1), wherein B is an ortho substituted monocyclic aryl or heteroaryl group or a bicyclic aryl or heteroaryl group; useful in the inhibition of one or more metalloproteinases, and in particular TACE.

  式（1）的化合物，其中B是一个邻位取代的单环芳基或杂环芳基或一个双环芳基或杂环芳基；在抑制一个或多个金属蛋白酶，特别是TACE方面有用。
• [EN] PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRAZOLOTRIAZINE ET/OU DE PYRAZOLOPYRIMIDINE PHARMACEUTIQUEMENT ACTIFS
  申请人：QURIENT CO LTD

  公开号：WO2019197546A1

  公开（公告）日：2019-10-17

  The present invention relates to pyrazolo [1,5 -a] [1,3,5 ]triazine and pyrazolo[1,5-a] pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazo lo [1,5-a][1,3,5 ]triazine and pyrazolo [1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.

  本发明涉及吡唑并[1,5-a] [1,3,5]三嗪和吡唑并[1,5-a]嘧啶衍生物及/或其药用可接受的盐，这些衍生物作为药用活性剂的使用，特别用于预防和/或治疗细胞增殖性疾病、炎症性疾病、免疫性疾病、心血管疾病和传染病。此外，本发明还涉及含有至少一种吡唑并[1,5-a][1,3,5]三嗪和吡唑并[1,5-a]嘧啶衍生物及/或其药用可接受的盐的药物组合物。
• ETHER DERIVATIVES
  申请人：Gobbi Claudio Luca

  公开号：US20080103174A1

  公开（公告）日：2008-05-01

  The present invention relates to ether derivatives according to general formula I, and to their pharmaceutically-acceptable salts, which may be used in treating or preventing cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, or psychoses comprising paranoia and delusions.

  本发明涉及根据一般式I的醚衍生物，以及它们的药用盐，可用于治疗或预防认知障碍、药物成瘾、抑郁症、焦虑症、药物依赖、痴呆症、记忆障碍、包括精神分裂症、情感性精神障碍、双相情感障碍、狂躁症、精神抑郁症、或包括偏执症和妄想的精神病等。
• ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2079693A1

  公开（公告）日：2009-07-22
• US7795437B2
  申请人：——

  公开号：US7795437B2

  公开（公告）日：2010-09-14